Genmab — Oktober 2017
-
129mill på en måned, er det ikke lettere optimistisk?
-
Nu var det en alt andet lige beregning. Combo i Europa og dara+pom i US må da for fanden snart få noget tracktion. Så oktober forhåbentlig
-
The alliances are focused on three key areas: infectious diseases including HIV, respiratory illnesses such respiratory syncytial virus (RSV), and infections acquired in health facilities like hospital-acquired flu. In addition to the research deals, Vir has also acquired Humabs BioMed, a Swiss company that’s developing more than 15 antibodies to treat diseases ranging from Zika to hepatitis B
-
Men vi har jo ikke rigtig set resultater af dara+pom label expansion i omsætningen endnu
-
Spændende virksomhed. Og sikke perspektiver!
-
Der er en del, der har efterlyst forklaringer. At udlægge det som negativitet giver ingen mening
-
Jeg har allerede budt ind med 81-82m svarende til 4,1m Per klinikdag
-
-
Ja. Tallene for juli var en stor skuffelse. Jeg havde regnet med effekt fra dara+pom, men den udeblev
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind